Computational Modeling of the Human Microbiome by Chowdhury, Shomeek & Fong, Stephen S.
Virginia Commonwealth University 
VCU Scholars Compass 
Chemical and Life Science Engineering 
Publications Dept. of Chemical and Life Science Engineering 
2020 
Computational Modeling of the Human Microbiome 
Shomeek Chowdhury 
schowdhury2@mymail.vcu.edu 
Stephen S. Fong 
Virginia Commonwealth University, ssfong@vcu.edu 
Follow this and additional works at: https://scholarscompass.vcu.edu/clse_pubs 
 Part of the Engineering Commons 
 
© 2020 by the authors. This article is an open access article distributed under the terms and conditions of 
the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
Downloaded from 
https://scholarscompass.vcu.edu/clse_pubs/28 
This Article is brought to you for free and open access by the Dept. of Chemical and Life Science Engineering at 
VCU Scholars Compass. It has been accepted for inclusion in Chemical and Life Science Engineering Publications 




Computational Modeling of the Human Microbiome
Shomeek Chowdhury 1 and Stephen S. Fong 2,*
1 Integrative Life Sciences, Virginia Commonwealth University, 1000 West Cary Street, Richmond, VA 23284
USA; schowdhury2@mymail.vcu.edu
2 Chemical and Life Science Engineering, Virginia Commonwealth University, 601 West Main Street,
Richmond, VA 23284, USA
* Correspondence: ssfong@vcu.edu
Received: 16 December 2019; Accepted: 27 January 2020; Published: 31 January 2020


Abstract: The impact of microorganisms on human health has long been acknowledged and studied,
but recent advances in research methodologies have enabled a new systems-level perspective on
the collections of microorganisms associated with humans, the human microbiome. Large-scale
collaborative efforts such as the NIH Human Microbiome Project have sought to kick-start research
on the human microbiome by providing foundational information on microbial composition based
upon specific sites across the human body. Here, we focus on the four main anatomical sites
of the human microbiome: gut, oral, skin, and vaginal, and provide information on site-specific
background, experimental data, and computational modeling. Each of the site-specific microbiomes
has unique organisms and phenomena associated with them; there are also high-level commonalities.
By providing an overview of different human microbiome sites, we hope to provide a perspective
where detailed, site-specific research is needed to understand causal phenomena that impact human
health, but there is equally a need for more generalized methodology improvements that would
benefit all human microbiome research.
Keywords: human microbiome; genome scale modeling; DNA sequencing; human health
1. Introduction
Interest in microorganisms associated with the human body has a long history dating back to
the handcrafted microscopes built by Antonie van Leewenhoek in the 1670s, where bacteria in van
Leeuwenhoek’s oral and fecal samples were referred to as “animalcules” [1]. As research techniques
and knowledge increased, human-associated microorganisms continued to be studied (e.g., use of
Hungate tubes to isolate anaerobic microbes [2] and documented (e.g., book titled “A Flora and Fauna
within Living Animals” in 1853). The accumulation of research has led to the current concept of the
human microbiome that has been described as an ecological community of commensal, symbiotic
and pathogenic microorganisms that literally share our body space and have been all but ignored as
determinants of health and disease [3].
Early glimpses into the complexity of the human microbiome started in the 1980s where diverse
microorganisms such as S. aureus, E. coli and Viridans were found by Rotimi et al. in the umbilical,
oral and fecal flora of neonates [4]. More recently, Pasolli and co-workers examined the microbiomes
at the four human anatomical sites: stool, vagina, skin and oral, using large-scale metagenomic
approaches and found ~150,000 microbial genomes coming from 4930 species (~total number of
species in the human microbiome) [5]. Interestingly, 77% (3796) of the identified species were novel
species whose genomes were not present in any of the public repositories. The scope and novelty
of composition was further emphasized where it was noted that ~75% genes associated with the
human microbiome lack functional annotation meaning that there is a large amount of “functional
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dark matter” associated with the human microbiome [6]. Apart from genes, proteins and metabolites
in the human microbiome, recently, researchers have found that human microbiome is not restricted to
only microbes and their metabolites, genes and enzymes. Small proteins or microproteins (less than
50AA) have been regularly found in human microbiome with the possibility of millions of small open
reading frames (ORFs) or microproteins being present [7]. The possible functions of the microproteins
include: housekeeping, bacterial adaptation, bacterial defense against phages and microbe–microbe
and microbe–host cell communication. These types of novel findings indicate the mysterious side of
the human microbiome. Ursell et al. and Gilbert et al. have already suggested that human microbiome
is still highly unexplored [8,9].
16S rRNA sequencing has been the standard and regular approach to find the species composition
of the human microbiome [10]. The hypervariable regions V1–V3 and V3–V5 of the 16S rRNA gene
help in identifying the taxonomic composition of various bacterial species. People have clustered this
gene into operational taxonomic units (OTUs) to investigate the microbiota composition in healthy
humans [11]. Sanger sequencing has been the standard method to sequence the complete stretch of
the amplicon (16S rDNA) [12]. However, people realized that species composition can be identified
using shorter DNA stretches with higher sequence coverage and thus next generation sequencing
(NGS) technologies, i.e., Roche 454 pyrosequencing, Illumina and Ion Torrent sequencing [12] are also
used for meta-genomic sequencing. Later, many computational approaches have also been developed
to analyze the 16S rRNA sequences of both disease and non-disease causing microbes to better
understand their biology in the human microbial communities [10,13]. However, even if we have good
coverage and longer sequencing reads using 16S rRNA sequencing, it will always be hard to obtain the
genomic information of low abundance species [6,10]. Therefore, recent research has shifted to using
high-throughput data techniques to produce both the qualitative and quantitative knowledge of the
DNA, mRNA transcripts, metabolites, and proteins of the microbial groups in the microbiome [14,15].
Meta-omic approaches can help provide a more comprehensive functional view of microorganisms and
their roles within the microbiome. Shotgun metagenomic sequencing was the first step in this direction
where bacteria’s whole genomic DNA from human/environmental samples is analyzed for both species
identification and understanding gene function potential of the microbe [12,16]. Another example is
the HMP Unified Metabolic Analysis Network (HUMAnN) that performs metabolic and functional
reconstructions of metagenomic data [17]. This method was applied on seven primary human body
sites including stool, tongue dorsum and anterior nares on 102 individuals. They identified the core
metabolic pathways, genes and functional modules which were different for different sites across
individuals. In the vaginal microbiome, it was found that glycosaminoglycan degradation, phosphate
and amino acid transport are more active in this microbiome [18].
Building upon the increased experimental data generated through the high-throughput approaches,
computational modeling approaches such as genome scale metabolic models (GEMs) have been
developed to integrate and analyze data to study function (Figure 1). In recent years, meta-omics data
have been used in conjunction with genome scale metabolic models (GEMs). This is illustrated in
Table 1, where omics and meta-omics data were used in the majority of the GEM studies. Genome
scale metabolic models and metagenomics data is taken as an input when you are using MAMBO
(Metabolomic Analysis of Metagenomes using fBa and Optimization) [19]. This research study used
this approach where they incorporated 1500 microbes in their model and showed that a distinct
metabolome exists at vagina, stool, skin and oral sites in the human body [19]. Use of in vitro, ex vivo
and in vivo experimental data with in silico models serve as the excellent research pipeline to discover
the unknown microbe–microbe and microbe-host metabolic interactions in human microbiomes
suggesting crucial therapeutic advancements [14]. While each of the respective omic data types
provide useful information in characterizing organism function, some of the data types are more
directly converted to the modeling formalism than others. For example, Vanee et al. used a proteomics
derived model to understand the metabolism functionalities of the microbe Thermobifida fusca where
the growth rates shown by experimental and in silico data were almost similar [20]. If experimental
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and computational work is properly used collaboratively, there will be identification of not only the
representative species of the human microbiome but of the other unknown species with whom these




 Figure 1. Complete human microbiome research pipeline established over the years explaining the
integration of experimental and computational methodologies to get the mechanistic understanding of
the human microbiome.
Computational analyses such as network analysis, agent-based modeling, and genome scale
metabolic modeling (GEM) have used to study various aspects of the human microbiome including
structure, dynamics, and coordinated function [22–24]. While a variety of specific analyses are
encompassed in network analysis, generally this approach considers connectivity of components
to consider structure-function relationships. This type of analysis often leads to the identification
of critical, highly connected hubs/nodes and can provide insight into robustness to perturbations.
Agent-based modeling is a stochastic simulation approach where discrete agents are ascribed attributes
to represent a biological entity and allowed to interact dynamically with other agents. For example,
agents could be used to depict an enzyme and a substrate and different concentrations of these
could be simulated to study the time-course dynamics by changing binding affinities. Thus, system
function can be studied by modifying properties of an agent and running simulations to see effects.
Genome scale metabolic modeling is a modeling approach that formulates a model based upon
experimentally-established information such as gene content (genomic data) and biochemistry, and a
number of publications and reviews exist describing this method in detail [25]. By starting with gene
content and connecting associated enzymes with biochemical function, a stoichiometric matrix is
generated that allows simulations to be run that can be used to study a variety of biological systems
including human–microbe and microbe–microbe interactions [26,27]. A number of software packages
have been developed to support development and analysis of genome scale metabolic models including
the constraint based reconstruction and analysis (COBRA) Toolbox [28]. Reconstructed networks for an
organism represent the biochemical and genetic capabilities and can be analyzed by stipulating input
constraints to create a space of allowable flux distributions to elucidate all of the possible metabolic flux
states. Flux balance analysis (FBA) is the generic approach for calculating the flux/flow of metabolites
through the network in an organism and hence, predicting the growth phenotype of the organism
or rate of production of an important chemical compound [29]. It finds the optimal solutions to the
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objective function which basically depicts the biological function which the network is performing.
For example, if you want to predict growth, biomass production by the target organism is taken as
the objective function [30]. After predictions are made using FBA, validation with experimental data
or model reconciliation is achieved between experimental and computational models using various
algorithms [31–33]. This entire process of building, analyzing, and testing GEMs helps obtain a broad
functional understanding of an organism and subsequently helps analyze and predict difference
between organisms, for example, between pathogens and non-pathogens of gut microbiome to find
therapeutic targets [34].
Given that the human microbiome involves numerous interacting species, community genome
scale metabolic models are definitely required for capturing the microbiome biology in a comprehensive
manner [26,28,35]. However, community genome scale modeling has challenges that need to be
addressed. First, most of these studies have been done on individual species because the number of
species of the human microbiome which have models is very low (~25) [21,28,35]. In the biological
world, there are of course not one or two, but multiple species working either in a cooperative or
competitive way in the complex microbiome. This brings us to the second challenge which is specifying
a global objective function for the whole community of microbes. People, however, have constantly
made efforts to tackle this problem by designing constraint based/genome scale modeling software
packages. A python software tool called Micom was developed which can take into consideration the
objective functions for both individual species and the microbial community including ~100 species at
a time [36]. Baldini et al. have created a MATLAB based software called Microbiome Modeling Toolbox
which applies genome scale modeling to simulate pairwise microbe–microbe and human–microbe
interactions [27]. Compartmentalization is the third challenge where reactions and the metabolites in
microbiome are needed to be partitioned correctly in the appropriate compartments (species or cell
organelles) [6,35].
There is microbial diversity across each of the human microbiome sites (gut, oral, skin and
vagina) and temporal diversity meaning varied biogeography dynamics exist for each of these sites
which advocates a more directed research towards personalized medicine for combating the human
microbial diseases [8,9,37]. The microbial behaviors and the molecular mechanisms at these different
human anatomical areas is different from each other [5,8,9]. The vast and complicated nature of
the human microbiome (the microbiome between two individuals is 80%–90% different compared
to the human genome which is 99.9% similar among individuals [8]) has even given rise to a new
multidisciplinary field of systems microbial medicine where experts from a wide range of fields
like microbiology, genetics, mathematics, statistics, engineering, computational biology, nutrition,
immunology, neurology and endocrinology are required to work together to get insights to human
microbiome [38]. The Human Microbiome Project (HMP) was a great initiative in this direction where
experts from different areas are trying to investigate different aspects of human microbiome like species
composition, metabolome, microbe–microbe interactions [39].
Studying the human microbiome is a challenging endeavor, but the connection to human health
is becoming clearer as the four major human microbiomes (skin, oral, gut, and vaginal) have their
own associated diseases: Crohn’s disease and obesity in gut, bacterial vaginosis and preterm birth in
vaginal, periodontitis in oral, atopic dermatitis in skin [40–44]. Therefore, there is a huge need to study
the human microbiome at these four anatomical sites in depth. Our review covers the background,
high throughput studies, and modeling methodologies employed to study each of the four distinct
microbiomes (gut, oral, skin and vaginal). Bringing all of them under one banner will help us to
get a holistic view of the global human microbial interactions which can be used in future for the
development of effective and novel treatment strategies.
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2. Human Gut Microbiome
2.1. Background
The longest established human microbiome had foundations in early work identifying
microorganisms associated with the gastrointestinal tract. Current concepts of the gut microbiome
dates back to 1965 when people found that gut microbes are not only present in the large intestine
but also in the stomach and small intestine [45]. Early research in this area mainly utilized culturing
techniques where researchers isolated the bacteria from the GI tract (Lactobacilli, Streptococci, Bacteroides)
and could test effects by feeding germ-free mice with a diet contaminated with isolated bacteria [46].
Zoetendal et al. in 1998 using temperature gradient gel electrophoresis of 16S rRNA proved that
every human has their own distinctive fecal microbiome [47]. Yatsunenko et al. showed that gut
microbiome is unique for every individual by characterizing the bacterial species from fecal samples of
individuals of different ages, living in different locations and also having different cultural traditions,
diet and lifestyle [48]. External factors including diet, antibiotics, lifestyle and even occupation alter
microbial niches to a great extent. Apart from that, the dynamics of a diseased and healthy microbiome
are totally different. Obesity and diabetic patients have often witnessed a different gut microbiome
from healthy individuals where diet has been seen to change the microbiome dynamics hugely [49].
Research has also been conducted to understand how geography influences the gut microbiome.
For example, a comparison of the microbiomes of Nigeria and UK infants, small children and adults
was conducted [50]. Drastic differences in the species composition between these two countries were
identified and diet noted as a factor affecting the microbiome composition, however, diet had a minimal
effect in altering the microbiome of adults [50]. It was suggested that the microbiome which gets
established during childhood by the diet taken at that age will not change hugely as the person grows.
A major transition in microbiome composition occurred in the growth of infants to small children that
corresponds to the switch from liquid to solid food, thus there are multiple contextual and temporal
variables that can affect the microbiome [50].
Compositionally, there are often characteristic, dominant organisms associated with the gut
microbiome; however, low abundance species may play crucial roles as well. Low abundance microbes
follow a lottery-based schema where a single niche is occupied by a single species and other species are
completely excluded [51]. Dominant phyla like Bacteroidetes and Firmicutes do not exhibit competitive
lottery-based schema whereas low abundant species (Akkermansia, Dialister, and Phascolarctobacterium
genera) do. There is a restricted functioning of the metabolome of low abundance microbes as they
typically have a smaller number of total genes and do not have clear patterns of coexistence or resource
partitioning. Another study focused on low abundance microbes where they injected 11 strains of
commensal bacteria into mice [52]. These rare strains protected the mouse from foreign microbes like
Listeria monocytogenes and they were also responsible for producing anti-tumor immunity by causing
development, maturation, accumulation and induction of IFN_gamma+ CD8 T cells in the gut. Overall,
it has generally been found that a high diversity gut microbiome is favorable over a low diversity
gut microbiome.
Through various studies, it has been found that the gut microbiome is responsible for performing
metabolic functions which regulate host functions such as bile acid metabolism where the host
synthesizes bile acids and the deconjugation and transformation of bile acids is performed by the gut
microbes [40]. It was further found that the gut microbiome gets depleted in people with Inflammatory
Bowel Disease (IBD) compared to healthy patients, affecting bile acid metabolism.
Additional health effects of the gut microbiome are related to interactions with the immune
system. The gut microbiome has been shown to perform defense mechanisms against the foreign
pathogens called “colonization resistance” [53] where the microbiota protects the host from infection.
The probiotic strain Lactobacillus salivarius UCC118 protects the host from Listeria monocytogenes [53,54].
Given the protective role of the gut microbiome, pathogens have developed strategies to target the
microbiome as an infection mechanism. Citrobacter rodentium and Salmonella modify the host’s gut
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microbiome for their invasion by causing intestinal inflammation [54–56]. The knowledge of the
defense mechanisms by the foreign pathogens against host’s colonization resistance will definitely
have significant medical importance. Antibiotics also alter the gut microbiome significantly affecting
the host physiology to a large extent [57,58]. Consuming antibiotics when not required has been related
to several diseases like asthma and type 1 diabetes [59,60]. Other studies have also found new immune
mechanism which human microbiome show. The microbial metabolite short-chain fatty acids produced
by commensal bacteria have been shown responsible for differentiation and generation of regulatory T
cells whose main function is to maintain immune homeostasis [61,62]. Salicyl-azo-sulfapyridine (SAS)
is a drug which the intestinal microbiome metabolizes by reducing the azo bond [63]. This activity was
significantly reduced when neomycin was injected into rats which inhibits the intestinal microbiome
functioning. It has been also found that gut microbiome provides an important path between cancer
cells and immunotherapy treatment [64]. Commensal gut microbes cause inflammation, produce more
TNF from the myeloid cells and modulate the increased production of radical oxidative species (ROS)
from myeloid cells which results in effective immunotherapy treatment.
In the context of cancer, a highly diverse gut microbiome with dominant phyla of Ruminococcaceae
and Faecalibacterium showed effective anti-tumor response and improved the T-cell function in the
tumor microenvironment to anti-PD1 immunotherapy in melanoma patients [65]. A low diversity gut
microbiome with dominant phyla Bacteroidetes did not show any protective mechanisms against cancer.
Shift in the dominant phyla composition in the gut microbiome is an aspect which is very much
associated with obesity [66]. The species composition, metabolome, microbial environment all gets
altered during obesity. Another interesting property people have witnessed in gut microbiomes
associated with obesity is energy metabolism [67] where microbiota associated with obesity have
the ability to harvest more energy from the diet than in non-obese individuals. There is a need to
understand the complex interplay between host genetics and microbial community gene content to
investigate obesity. The biological properties of the ‘superorganism’ which forms when microbes and
their genes, enzymes and metabolites and host’s genes, enzymes and metabolites interact together
should be explored to get the insights to the obesity biology.
2.2. High-Throughput Studies
High-throughput approaches, i.e., 16S rRNA sequencing and metagenomics have been used in
many studies to identify the species composition in the gut microbiome. One of the ongoing challenges
in microbiome work has been the issue of identifying low abundance species [68]. For example, using
16S rRNA sequencing, they found two gut microbes which are in low abundance in the human colon:
Lachnospira pectinoschiza and another one similar to Planctomycetes (organism name was not known).
Wilson and coworkers using 16S rRNA sequencing identified new species colonizing human colon [68].
Similarly, human intestinal flora diversity have been explored using the same method leading to the
identification of many novel species where approximately 400 to 500 different species inhabit [69,70].
Furthermore, 16S rRNA sequencing studies found new metabolic pathways for glycans, vitamins and
amino-acids in the gut microbiome [71]. 16S rRNA sequencing has also been used to determine the
abundance levels of species in the gut microbiome during obesity. Ley et al. took samples of 12 obese
people and observed that relative abundance of Bacteroidetes was high and of Fimicutes was low [72].
These 12 obese people were then given restricted carbohydrate and fat diets. After weight loss, the gut
microbiomes of the 12 individuals were examined again using 16S rRNA sequencing and it was found
out that the relative abundance of Bacteroidetes decreased and that of Firmicutes increased. Biological
dynamics of the normal gut microbiome gets perturbed and altered during diseases like obesity, type-1
and type-2 diabetes and even atherosclerosis [41,73]. However, the limit in the read length in these
kinds of studies sometimes misses the detection of some bacterial species and strains [8]. Although,
this has been a long standing problem for now, people have already started making efforts to address
this issue by utilizing recently developed sequencing technologies [74,75]. These are one molecule real
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time technologies which have been shown to decrease the short read problems and furthermore, a
higher data yield at lower cost can be obtained by using this approach [76].
Recently, metagenomic studies have been employed to study microbiomes instead of 16S rRNA
sequencing due to the amount of bacterial DNA it can analyze to identify new species. For example,
a large study analyzed the gut microbiome samples of 11,850 people who live in South American
and African regions [77]. In total, 92,143 metagenome assembled genomes were used and 1952 new
bacterial species were found. Half of these bacterial species could not be classified even at the genus
level, demonstrating the amount of unannotated information that exists. Similarly, Nayfach et al.
analyzed 156,478 microbial genomes from fecal samples and found 23,790 species level operational
taxonomic units (OTUs) [78]. Among that, 4588 OTUs were from the gut microbiome out of which
2058 OTUs were newly identified.
One of the challenges with metagenomic studies is associated with how to deal with novel species
or genes that lack functional annotation. Binning is the principal approach in metagenomics for
grouping the contigs to specific operational taxonomic units (OTUs) [79]. Zhu et al. used binning
methods to identify the pathogenic species in the gut microbiome causing diarrhea [80]. Miller et al.
suggested that conventional metagenomic protocols including assembly and binning which are
performed using chemical and physical treatment of multiple tissue samples are unable to find low
abundant species [81]. However, they modified and improved the existing metagenomic methods by
focusing on single tissue sample without any external treatment and when applied to studying the
invertebrate Bugula neritina, seven novel bacterial genomes were identified [81]. Another study has
also tried to tackle these limitations of metagenomics by using targeted functional profiling as this
experimental approach is known to identify bacterial species and their genes [82]. It was conducted in
two manners: immunology based and non-immunology based. In the immunology based approach,
bacterial response to IgA was evaluated to identify the species and the genes. In the non-immunology
based approach, metagenomic DNA was expressed in a bacterial host and it was seen which genes are
expressed and define the functional phenotype. People have predicted the function of the nonribosomal
peptide synthetase (NRPS) gene that is serine protease inhibition using this method which they found
in the cells of a number of gut microbes including E. coli and B. subtilis.
2.3. Modeling Methodologies
A number of different computational modeling approaches have been developed to study the
gut microbiome to help analyze and understand its function including aspects of network topology,
metabolic function, microbe-host interactions, and microbe–microbe interactions. One of the early
computational studies of the gut microbiome used a network based approach where topological
properties of metabolic networks were examined to analyze obesity and IBD [24]. It was found that the
microbiome and associated metabolome has a large impact on host metabolism. Critical host enzymes
of the metabolic network were found not on the central part of the network but on the periphery.
It was suggested that these peripheral enzymes might be using bacterial metabolites which are unique
and the compounds produced by these enzymes will get released to the host environment due to
close proximity. Furthermore, these enzymes might be acting on the host metabolites to regulate the
host environment.
Genome scale metabolic models (GEMs) have also been utilized to study various aspects of the gut
microbiome including: microbe–microbe, host-microbe and diet-microbe metabolic interactions [83].
In addition to studying different interactions, GEMs have also been developed to analyze single species,
multiple species and communities in the gut microbiome [84].
E. coli which is the common microbe found in gut microbiome, the strain specific differences of
it have been examined using GEMs where metabolic reconstructions of the three common strains of
E. coli (HS, UTI89, and CFT073) found in gut were compared [85]. The optimal flux distribution for
each of the 3 strains were different but the optimal growth rate was the same and each strain had a
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distinct set of metabolic pathways explaining the reason for different strain of the same microbial
species giving rise to a different phenotypic function.
Additional application of single species GEMs associated with the gut microbiome consists of
three main areas: (1) construction of in silico growth media; (2) phenotype prediction of the gut
microbes; and (3) defining interspecies metabolic interactions [22]. In designing media, GEMs play
a crucial role by identifying the metabolites required and how growth is computed. Transcriptomic
and proteomics data is used by GEM to predict the phenotypes and explain the pathogenicity and
therapeutics of the microbes even at the strain level.
Single species GEMs also serve as the foundation for studying community population function.
One modeling approach is called mixed-bag network modeling [86]. This method takes the single
species GEM and merges it into one model with a single intracellular compartment. People have
used this methodology to understand the differences in the gut microbiome dynamics between
malnourished children from Bangladesh and Malawi and healthy children from Sweden [87]. Gut
microbiome is responsible for converting dietary macronutrients to health-promoting metabolites like
vitamins, amino acids (AA) and SCFAs. GEM was performed for 58 commonly found gut microbes
in both these populations and it was observed that gut microbiome dysbiosis is associated more
with malnourished children. Essential AA like lysine, tryptophan, and arginine are produced in low
amounts in malnourished children which act as precursors for many crucial metabolic pathways. GEMs
showed that Bangladeshi and Malawi malnourished children had less species diversity resulting in less
metabolome diversity and less essential AA production in comparison to Swedish healthy children.
Larger, multi-species genome scale metabolic modeling efforts such as CASINO and AGORA
are also now available as well as community based approaches that utilized metagenomic data to
study species co-occurrence as related to nutrient availability [88,89]. CASINO (Community And
Systems-level INteractive Optimization) is a toolbox focused on community metabolic modeling [90].
In developing CASINO, five dominant gut microbes were used to study microbe-diet interactions.
Assembly of gut organisms through reconstruction and analysis (AGORA) is the largest collection of
gut microbiome GEMs accounting for 773 gut microbes coming from 605 different bacterial species [91].
AGORA produced metabolically distinct reconstructions for each organism and experimentally
validated the carbon source uptake, fermentation product secretion and nutrient requirements of the
gut microbes. Pairwise interactions in both aerobic and anaerobic conditions for all organisms were
conducted. By also using the Recon 2 human metabolic model, it was demonstrated that human
metabolism and gut microbiome metabolism were interlinked [92–94].
After construction of a GEM, omics data can be integrated into the model to analyze various
phenomena associated with food-microbiota-gut dynamics [95–97]. The gut microbiome is the main
link between body’s diet and nutrient uptake and it performs important metabolic functions like
degradation of undigested polysaccharides and producing short chain fatty acids (SCFAs) [98]. Acetate,
butyrate and propionate have been the major SCFAs which microbes produce and transport. GEMs
have been used to study where SCFA transfer, ATP production and other growth strategies of the gut
microbes. Shoaie et al. have used genome scale modeling (GEM) to model the metabolic interactions
between the three dominant microorganisms of the gut microbiome; Bacteroides thetaiotaomicron,
Eubacterium rectale and Methanobrevibacter smithii [99]. They integrated transcriptomic data with GEMs
to evaluate the adaptation strategies of these organisms. SCFA production and consumption among
the three microbes was studied the diffusion coefficient of SCFA absorption by epithelial cells was also
calculated. Gut microbes mainly interact with the host through the exchange of bile acids, phenolic and
aromatic acids, cholines, fatty acids and phospholipids and interact among themselves through SCFAs
exchanges. Diet is the crucial factor in defining the function of the gut microbiome and metabolism of
three main macronutrients: carbohydrates, proteins and fats by the gut microbiome can be studied
using GEMs [100].
Another study investigated the effects of gut microbiome on host metabolism where GEM was used
to study the co-metabolism of host and microbe under four in silico dietary conditions: High-protein,
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High-carbohydrate, High-Fat and Western [101]. 11 common gut microorganism models were used in
conjunction with Recon 2 human metabolic model (human metabolism) [92]. It was shown that the gut
microbiome produces essential metabolites leading to hormonal homeostasis. In another study, GEM
was used to analyze the metabolic networks of infants before (1 and 3 months) and after (7 months and
1 year) solid food introduction [102]. The introduction of solid food precipitated changes in the gut
microbiome where metabolites like ferulate were produced (responsible for cognitive development
and neuroprotection).
To further facilitate research connecting the microbiome to the human host, the virtual metabolic
human database (VMH) was developed [103]. The database used five resources: Human metabolism
(Recon3D human metabolic reconstructions) [104], ReconMaps (seven human metabolic maps of
six organelles and one accounting for all of them including the reactions occurring in extracellular
space and cytosol) [94], Gut microbiome (818 manually curated GENREs of 667 species), Disease (255
mendelian diseases) and Nutrition (food database and diet database). They are linked through shared
nomenclature of metabolites, reactions and genes. The idea is a metabolic disease is not caused by
an individual factor but both external (diet, gut microbes) and internal (host genetics) factors are
important to consider. The VMH database contains 17,730 and 5180 unique metabolic reactions and
metabolites respectively, 632685 microbial genes and 3695 host genes, 255 diseases, 818 microbes and
8790 food items.
In addition to dynamics associated with food and species interactions, spatial and temporal
dynamics are important to consider. Species in the gut sometimes support each other’s growth by
metabolic cross-feeding while compete for the nutrients leading to the division of metabolic tasks.
BacArena, a community modeling tool was developed and applied on seven commonly found species
on the gut [105]. It integrates FBA and genome scale modeling (GEM) to look at microbial metabolism.
Individual models of the microbes are considered where the spatial and temporal status of the
metabolites in the gut microbiome are looked and then combined to understand the whole microbial
community. An agent based model called GutLogo has also been developed to study the spatial and
temporal dynamics [23]. Agent based model analysis showed that perturbation of the gut microbiome
using nutrition and probiotics alters it but when the perturbations are removed, it again comes back to
its original composition indicating the robust nature of this biological system.
Modeling and analysis of the gut microbiome has helped gain insight into a variety of diseases as
our understanding of the impact of the gut microbiome continues to expand. GEMs of 5 abundant
gut microbes and the human small intestine and human brain were combined to study autism
dynamics [106]. The model was combined with brain using PBPK transport model. The study was
able to capture some biomarkers depicting autism like pyruvate and lactate. Two studies utilized
GEMs of gut microbes to gain insights into the progression of colorectal cancer. The first study
evaluated hydrogen sulfide production which was higher for tumor cells than normal cells during
colorectal cancer [107]. 16S rRNA data was used as input to generate GEMs of the gut microbes
Fusobacterium nucleatum, Clostridium perfringens, Filifactor alocis and B. fragilis which showed higher
hydrogen sulfide production. GEMs showed higher flux for hydrogen sulfide and the metabolic
interactions among these microbes was analyzed to understand the mechanisms of its production.
A second study worked in a similar manner but the biological mechanism they focused on was the
mismatch repair system (MMR) during colorectal cancer [108]. They created GEMs of gut microbes
to understand the metabolic interactions in two types of microbial communities: dMMR (deficient)
and pMMR (proficient). B. fragilis and F. nucleatum had higher abundances in dMMR colorectal cancer
whereas B. fragilis had low abundance in pMMR colorectal cancer. GEM showed that hydrogen sulfide
production was higher in dMMR colorectal cancer and there were amino acid substitutions in place of
it in pMMR colorectal cancer produced in higher amounts. Different modeling studies performed on
gut microbiome along with the experimental data used in that study during disease and non-disease
scenarios is given in Table 1. The table also lists the modeling studies performed on other three
microbiomes: oral, skin and vaginal microbiome.
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Table 1. Summative table of all the modeling studies performed on Gut, Oral, Skin and Vaginal
microbiome during disease and non-disease scenarios.
Non-Disease Disease Experimental Data Modeling Approach Reference
GUT MICROBIOME
Microbe–host–diet







Genome Scale Modeling [103]
Gut microbiome
dynamics in infants and
small children
Metagenomics Genome Scale Modeling [102]
Host–food–microbiome
interplay
Omics data of various















Metagenomics Genome Scale Modeling [91]
Gut host-microbe
metabolism Metagenomics Genome Scale Modeling [101]




















Metabolomics Genome Scale Modeling [97]
Host-microbe
interactions
Omics data of various























Metabolomics Genome Scale Modeling [83]
Gut metabolome
investigation Metabolomics Genome Scale Modeling [110]
E. coli metabolism Deep sequencing/NGS Genome Scale Modeling [85]
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Table 1. Cont.
Non-Disease Disease Experimental Data Modeling Approach Reference
GUT MICROBIOME
Malnutrition Metabolicprofiling/Metabolomics Genome Scale Modeling [87]
Spatial and temporal
dynamics Metagenomics Agent Based Modeling [23]
Autism Metabolomics Genome Scale Modeling [106]
Colon cancer Omics data of varioustypes Genome Scale Modeling [107]
Colorectal cancer Metabolomics Genome Scale Modeling [108]
ORAL MICROBIOME
Periodontitis Transcriptomics Genome Scale Modeling [111]




































Genome Scale Modeling [118]
3. Human Oral Microbiome
3.1. Background
In 1684 Leeuwenhoek wrote a letter to the Royal Society of London stating “The number of animals
in the scurf of a man’s teeth is so many that I believe they exceed the number of men in a kingdom” [119].
As many as 700 microbial species reside in the human oral microbiome. The oral cavity is complex
because of the different microbial niches allowing for diverse local environments. The different oral
sites are teeth, the gingival sulcus, the tongue, mouth floor, cheek, hard and soft palates, tonsils, throat
and saliva [119]. People have used different experimental approaches to investigate oral microbiome:
culturing, microscopy, gel-based techniques, next generation sequencing (NGS), DNA microarrays,
DNA hybridization, 16S rRNA sequencing and PCR [119,120]. The challenges that people face when
they are dealing with oral microbiomes is bacteria in this microbiome form biofilms which is a complex
microbial community [119,120]. They form stable metabolic interactions in biofilms which help them
in their survival and growth. The biofilm formation helps the oral microbes to maintain homeostasis,
prevent disease development and protect the oral cavity [120]. Apart from that, researchers have tried
to find the reason behind the spatial organization of oral microbes i.e., if an oral microbe is present
in a particular location in the oral cavity, why it is actually present there [121]. In a dental plaque
microbiome, Corynebacterium is present in the biofilm matrix attached to the tooth as it holds the
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entire microbiome structure. Streptococcus is present in the periphery where they get an oxygen rich
environment with access to sugars.
Biofilm disruption and oral microbiome imbalance causes diseases and dysbiosis in the oral
microbiome [120]. Two widely known oral diseases; dental caries and periodontitis are caused by
Streptococcus mutans and Porphyromonas gingivalis respectively. People have used NGS to identify
novel species in both these diseases like Granulicatella, Leptotrichia, Neisseria bacilliformis in caries
and Prevotella spp. in periodontitis [119]. It is not a single oral pathogen or group of pathogens
which cause oral diseases but rather the collection of microorganisms. Apart from caries, periodontal
and other mucosal diseases which are local oral diseases, imbalance in oral microbial flora has
been linked to several whole-body systemic diseases like atherosclerosis, HIV, polycystic ovarian
syndrome (PCOS), Alzheimer’s disease, inflammatory bowel disease (IBD), liver cirrhosis, diabetes
and obesity [122]. Therefore, exploring these microbiomes will be helpful to develop human health
improvement strategies as it shows effects on the whole body at various anatomical sites.
As with the gut microbiome, there is a large number of novel, unknown species in oral
microbiome [120]. Dewhirst et al. created the Human Oral Microbiome Database (HOMD) where they
performed phylogenetic analysis for the oral microbes at different locations from teeth to tonsils [123].
16S rRNA gene sequence analysis identified 1179 taxa of which just 24% were named and 68% were
uncultivated from 36,043 16s rRNA gene clones. To further support the scope of the oral microbiome,
Benn et al. stated ~700 bacterial species are found in the oral microbiome out of which 50% of them
have not been cultivated yet [119]. Of the known species and function, it has been found peptidic small
molecules (PSMs) are common in the oral microbiome [124]. Oral microbes secrete and release PSMs
and exchange it among themselves with other metabolites which are responsible for giving structure to
the microbiome [124]. Even though PSMs can be detected using liquid chromatography-tandem mass
spectrometry (LC-MS/MS), researchers noted that there is a huge “black box” in this area and deeper
understanding of the oral microbial interactions is required to identify more PSMs and the processes by
which they are differentially produced. These studies show that the oral microbiome is actually highly
unexplored with a large number of unknown species and unique molecules, metabolites, metabolic
genes and pathways.
3.2. High-Throughput Studies
16S rRNA sequencing has been the most popular high-throughput approach to identify novel
members in the oral microbiome [125]. Rothia are generally found at tongue or tooth surfaces,
Streptococcus salivarius colonizes the tongue, Simonsiella colonizes mainly the hard palate and Treponemes
can be found only at the subgingival crevice. The oral microbiome diversity is huge as 400–500 different
bacterial strains are only found at subgingival crevice [126]. Fusobacteria, Actinobacteria, Proteobacteria,
and Cytophagales are the four bacterial divisions mostly seen there but they hypothesized that more
unknown taxonomic divisions are expected in this anatomical site.
Demmitt et al. performed another study where they used genome wide association studies
(GWAS) for analyzing the oral microbiomes of 752 twin pairs [127]. They wanted to understand the
genetic factors or identify the genes which regulate oral microbiome development. It was found that
the host genes actually influence the oral microbiome to a great extent. The human genes were found
on chromosome 7 and 12 which seemed to correlate with the oral microbiome while external factors
like tobacco, marijuana and alcohol do not appear to have as strong an influence.
As one of the major diseases associated with the oral microbiome, periodontitis is a focal point
of oral microbiome research. One study used shotgun metagenomic sequencing and phylogenetic
diversity to understand periodontitis dynamics [128]. Additional keystone pathogen species like
Haemophilus haemolyticus, Prevotella melaninogenica, and Capnocytophaga ochracea were identified which
function in a similar way as Porphyromonas gingivalis (the main microbe causing periodontitis) in
altering the oral microbiome. These three microbes are less abundant like P. gingivalis and promote
inflammation by perturbing host-microbe interactions which try to inhibit the disease. Through the
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use of deep sequencing, microbes association with periodontitis can be suggested as well as a trend
where health oral microbiomes are mainly composed of gram positive bacteria [43]. The shift to a
diseased state and dysbiosis happens with accumulation of a broad range of gram negative bacteria,
more complex metabolic interactions and increased availability of nutrients to the microbes due to
damaged oral tissues. This is also reflected by a decrease in alpha diversity of the oral microbiome
which is associated with periodontitis [128].
3.3. Modeling Methodologies
A small number of studies have used network analysis or genome scale modeling to study the oral
microbiome. Network analysis was used to analyze the co-occurence mechanisms among oral microbes
and gut microbes [114]. It was found that Neisseria elongata and Granulicatella adiacens were involved
in causing metabolic syndrome (MetS). Currently, there are some conflicting results on the effects of
external factors like diet, smoking, personal hygiene and medication on the oral microbiome [114,127]
and it is expected that additional studies and analysis can help reconcile mechanisms lead to disease
states. Another study performed metabolic reconstructions for 456 oral microbial strains using their
genomic information [113]. Then, they applied network robustness analysis on the metabolic networks
of these microbes to observe the biosynthetic capabilities of them. The function of 97 metabolites across
the 456 microbial strains was determined to explore the cross-feeding and metabolic interdependencies
among the oral microbes.
A genome scale metabolic model (GEM) of P. gingivalis has been reconstructed containing 679
reactions and 564 metabolites [112]. Analysis of this model indicated that P. gingivalis produces
succinate, butyrate and propionate after amino acid catabolism. This is a strategy to harm host cells
and feed its oral partners with essential nutrients. Furthermore, succinate produced by another oral
pathogen is used to produce ATP. The GEM of P. gingivalis was also used to study synthesis pathways
for lipopolysaccharides (LPS) which can potentially be targets for therapeutic applications [112]. P.
gingivalis secretes gingipains which perform C5 convertase complement signalling with TLR2 protein
leading to dysbiosis and inflammation in the normal oral microbiota [111]. The abundance of microbes
present in a healthy microbiome gets disturbed due to the microbial dysbiosis caused by less abundant
P. gingivalis. Hence, community metabolic modeling using GEMs involving this pathogen and its other
oral partners will give us more answers to the biological dynamics of periodontitis which will help us
in defining the therapeutics for this disease.
4. Human Skin Microbiome
4.1. Background
With constant exposure with the outside world, the skin microbiome has the potential to be
highly variable. Skin has different types and each type has its own microbiota composition and
associated disease [129]. For sebaceous skin, Corynebacterium and Propionibacterium are found and
associated with acne. Atopic dermatitis is found on moist skin and is associated with Staphylococcus
and Corynebacterium. Psoriasis is a dry skin disease and species found there are Corynebacterium,
Propionibacterium, Staphylococcus and Streptococcus. Given the diversity of skin types, diseases,
and associated organisms one of the first needs is to identify and categorize the microbiota present.
Bewick et al. tried answering these questions by performing trait based analysis on 971 skin microbial
taxa to classify the organisms based upon various enzymatic or biological characteristics [130].
While generally showing high compositional variability, the skin microbiome shows higher
variability between individuals with less variability in a single individual across different skin sites.
Due to high interpersonal variations in these microbiomes, people have tried to study what are the skin
microbes which actually differ between individuals [131]. 263 specimens were collected from 15 healthy
adults (nine males, six females) from 18 defined anatomical skin sites. There were individual specific
signature species in the skin microbiome which were found across all the skin sites in an individual but
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in low abundance. Sometimes the variation in the skin microbiome among different individuals is due
to strain variations such as was found for different strains of P. acnes [131,132]. Genome sequencing
and metagenomic studies of P. acnes showed that R2 and R6 strain of this bacterium are commensal
ones whereas R4 and R5 strain showed strong link with acne [133]. They also identified the genetic
determinants in P. acnes strains responsible for acne pathogenesis. Other than P. acne, M. tuberculosis,
M. leprae and S. aureus are other bacteria which show this phenomenon [132]. Staphylococcus epidermidis
is interesting as different strains of it are found at different body sites of an individual but the same
strain of it has been found on different individuals. [131,132].
Atopic dermatitis causes dysbiosis in the skin microbiome which leads to an imbalance in the
microbial populations consisting of Propionibacterium, Corynebacterium and Staphylococcus epidermidis
which make allergens and pathogen associated molecular patterns (PAMPS) enter the skin easily [134].
To study atopic dermatitis, MiSH (Microbial index of skin health) was calculated for 25 skin bacterial
genera from population samples from two Chinese cities and one American city [44]. For both these
populations, it was observed that S. aureus is highly abundant in atopic dermatitis patients than the
healthy patients indicating it as a global phenomenon [44,134].
In addition to site specific diseases, the skin microbiome plays a huge role in immunity. It prevents
the invasion of the foreign pathogens, so, it is necessary to maintain the skin microbiome properly
to live healthy [134,135]. Skin is not an ideal environment for microbes as they get low amount of
nutrients, are always attacked by antimicrobial peptides and have an acidic, cool, salty and a desiccated
atmosphere. Yet human and skin microbes have shown coevolution for their own benefit [135].
Primary immunodeficiencies (PIDs) are characterized by depleted memory T and B cells, changing
eosinophil concentrations, high IgE levels and atopic dermatitis like skin disease [136]. In PID patients,
S. epidermidis, S. aureus and S. marcescens were present in high abundance [136]. It was assumed that
S. epidermidis may coordinate with S. aureus during PID in a mutualistic or commensalistic way enabling
greater resistance by S. aureus to S. aureus antibiotics and other antimicrobial peptides. The skin of PID
patients face selective pressures due to which different microbes try to take advantage of local changes
such as Serratia marcescens being found on the skin of immunodeficient patients [136]. Another study
showed that S. epidermidis can serve as a protective agent by inhibiting S. aureus biofilm formation [137].
The commensal form expresses a serine protease glutamyl endopeptidase (Esp) which degrades the
proteins of S. aureus which they use for forming biofilm. This study also showed that S. aureus also
switch to commensal form from pathogenic form when it interacts with Corynebacterium striatum [137].
4.2. High-Throughput Studies
The skin microbiome aids in protecting us from the invasion of the foreign pathogens, so, a great
deal of biology is involved in the skin microbiome among the skin microbes and analyzing their
metabolic interactions will give us several insights into the various skin diseases [138]. Use of amplicon
sequencing and shotgun metagenomic sequencing has identified several fungal species (Malassezia
spp., Aspergillus spp) and viral species (Merkel cell polyomavirus and Molluscum contagiosum virus) that
are also present in skin microbiome but in very low abundance [137]. Generally, all experimental
techniques (culturing, sequencing, etc.) are difficult due to the high variability that is possible in the
skin microbiome including intrinsic factors like age, genetic make-up and host immune system and
temporal changes in composition due to shifts in environmental exposure [139].
As with other microbiomes, 16S rRNA sequencing has been a primary method used to identify
species associated with the skin microbiome. Due to the potential for variation of the skin microbiome
on the same person, often multiple sampling methods can be used within the same study. For example
three sampling methods: swab, scrape and punch biopsy were used to collect the samples from
the inner elbow to study atopic dermatitis [140]. Various bacteria from Proteobacteria, Actinobacteria,
Bacteroidetes and Firmicutes were found using the different sampling methods. Two indexes, Jabund
and SONS assess the community similarity which showed that left elbow and right elbow had the
same microbial community structure [140].
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Interestingly, the skin microbiome appears to be temporally stable [141]. This time invariance
was demonstrated using shotgun sequence data of skin microbes from 594 samples from 12 healthy
individuals that were sampled across 17 skin sites at three time points. External and internal factors may
play a crucial role in altering skin microbiome because without these perturbations, skin microbiome
did not change at all [141]. There is a need to find how different factors perturb this stability and how
the signature microbes in the skin microbiome maintain this stability. The human skin microbiome
is very different from not only primates but from other mammals [142] with the human microbiome
having dominant species of S. epidermidis, Corynebacterium, and Propionibacterium acnes. These species
are not found in the skin microbiomes of other mammals. The reason for this distinction in the human
skin microbiome is because of the general human practices which we do every day like clothing, living
in a built environment and washing with soap etc. This has enabled the human skin microbiome to
have a distinct species composition. This study was conducted using 16S rRNA sequencing targeting
hypervariable regions (V3–V4) in the microbial RNA [142].
4.3. Modeling Methodologies
Network analysis was applied on skin microbiome to understand the topographical distribution of
skin microbes at the three skin sites: moist, sebaceous and dry areas [115]. Each of these sites has their
own microenvironment with their own set of species and metabolites. Moist skin microbes outnumber
sebaceous skin microbes and moist and sebaceous microbe members frequently group together
depicting high number of metabolic interactions happening between these two communities [115].
Bottom-up ecology is a biological phenomenon which says that for a microbiome, the metabolic
potential of it which is depicted by the ability to use the metabolic resources effectively can be
known from genes, metabolites and interactions among them in the species [116]. This study used
genome scale modeling (GEM) to investigate this concept in skin microbiome. They found the top
10 metabolites/compounds which are present in higher amount in the skin microbiome. These were
the ones which are regularly found in cosmetics and hygiene products like myristic acid, citrate,
N-acetyl glucosamine etc. [116]. These results show that external factors somehow do influence the
skin microbiome to a great extent.
5. Human Vaginal Microbiome
5.1. Background
Vaginal microbiome research is the most new one if compared with microbiome research in the
other three anatomical sites; gut, oral and skin. Currently, more than 100 to 200 bacterial species
have been found associated with the vaginal microbiome [143]. Lactobacillus (L.) is the dominant
genera and is typically associated with a healthy vaginal microbiome. They are responsible for the
low pH we usually see in this microbiome, i.e., 3.8 to 4.5 [143] which helps prevent proliferation
of nonindigenous organisms and helps in defense against the foreign pathogens that can cause
dysbiosis and vaginal infections [144]. Interestingly, even though Lactobacilli are common in the vaginal
microbiome, the ethnicity of an individual appears to influence the specific species with L. iners found
in White/Caucasian people, L. crispatus in Asian women and L. jenseni found in Black and Hispanic
women [143]. However, a significant number of healthy women also have vaginal microbiome
which is not dominated by Lactobacillus species with 40% of Black and Hispanic populations having
non-dominated lactobacilli vagitypes [144,145]. Even in non-Lactobacillus dominated microbiomes,
other bacteria perform homolactic and heterolactic acid fermentations indicating the importance of
lactic acid production.
The species distribution in the vaginal microbiome can be consistent across individuals as similar
vagitypes have been identified across individuals, which is not the case for other microbiomes as
we mentioned above. Community state types (CSTs) which have been classified according to the
dominant species found within a vagitype. CST1, CST2, CST3, and CST5 are vagitypes dominated by
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Lactobacillus species. CST1 comprise L. crispatus as dominant species, CST2 is dominated by L. gasseri,
CST3 consists of L. iners as dominant species and CST5 has L. jenseni [146,147]. CST4 is dominated by a
diverse group consisting of anaerobic bacteria: Prevotella, Dialister, Atopobium, Gardnerella etc. with low
proportions or no detectable Lactobacillus species [144]. Vaginal bacterial communities dominated by
Lactobacillus spp. i.e., CST1, CST2, CST3 and CST5 were found in 80.2% and 89.7% of Asian and white
women, respectively and in 59.6% and 61.9% of black and Hispanic women, respectively. Communities
with low proportions or no detectable Lactobacillus species community state type, i.e., CST4 were
elevated in Hispanic (38.1%) and black (40.4%) women compared with Asian (19.8%) and white (10.3%)
women [144,146]. People have also defined some other CST types i.e., CST6 which is dominated
by G. vaginalis, CST7 comprise BVAB1 (Bacterial Vaginosis associated bacteria-1); CST9 consists of
G. vaginalis and L. iners as dominant species [147].
A shift in the composition of the microbiome leads to dysbiosis and potentially bacterial vaginosis
(BV) that is characterized by a shift away from Lactobacilli and a change in the properties of the vaginal
fluid [143]. Clinically, bacterial vaginosis is characterized by a Nugent score between 7 to 10 and
can be a cause of preterm birth [42,148]. BVAB1 and G. vaginalis are currently considered the main
causative agents for bacterial vaginosis and their presence often coincides with an increase in the
local pH [145]. There are a set of intrinsic and extrinsic factors which are responsible for causing this
dysbiosis. Internal factors are genes, innate and adaptive immune mechanisms and external factors are
antibiotics, hormonal contraceptives, birth control methods, sexual activity, vaginal lubricants and
douching which can cause disturbance to this microbiome [145]. CST4 is considered as the vagitype
which has the highest ability to cause bacterial vaginosis [146]. L. iners has been associated with
dysbiosis as it has been observed that L. iners number increase in a dysbiotic vaginal microbiome [143].
CST3 is the vagitype dominated by L. iners. It has been observed that CST6 and CST9 which are BV
associated microbiomes, transitioned to CST3 after BV medication was taken [147]. Hence, medication
decreased the risk, but the treatment was not fully effective. It is because L. iners use the high pH of a
dysbiotic microbiome to perform cooperative interactions with BVAB1. CST1, CST2 and CST5 did not
show any kind of transition even after BV medication which shows that if the microbiome is healthy it
has a certain degree of robustness to change [147].
Ethnicity of a person has been associated with a particular type of vaginal microbiome.
The microbiomes in African-American women are more diverse and with a higher number of
BV-associated bacterial species such as G. vaginalis, L. iners, BVAB1, Mycoplasma hominis, Aerococcus and
other anaerobes like Anaerococcus [148]. Caucasian women were more likely to be colonized with L.
crispatus, L. jensenii, L. gasseri and Staphylococcus. In a comparison of African-American and European
women, it was found that African-American women are 2.9 times more likely to be diagnosed with
BV and European women had 25.8% less BV-associated bacteria [148]. Pregnant women who were
African-American showed higher risk of preterm birth than European pregnant women [148].
5.2. High-Throughput Studies
As with most of the human microbiome projects, 16S rRNA sequencing has been used for initial
analysis and identification of microorganisms, such as the identification of the dominant Lactobacillus
species through measurement of samples from women from different countries [149]. Studies have
also been conducted to determine if the vaginal microbiome has variation in composition within the
same person. For example, 10 Finnish women had bacterial DNA from 6 different vaginal locations
using 4 different sampling strategies tested and generally, the microbial composition was shown
to be consistent regardless of sampling site or strategy [150]. Based upon 16S rRNA sequencing,
a vaginal microbiome database (Vaginal 16S rDNA Reference Database) has been created containing
information of bacterial species in the vagina [151]. This database contains information from 1017
mid-vagina samples and approximately 30 million 16S rDNA reads. Species classification was based
on hypervariable regions from V1 to V3 in the 16S rDNA using the STIRRUPS algorithm [151].
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More recent studies have sought to leverage high-throughput sequencing to gain additional
insight into the microorganisms in the vaginal microbiome [42,152]. For example, vaginal microbiome
samples from 310 healthy Canadian women were analyzed using massively parallel sequencing of the
universal target (UT) of the cpn60 gene [152]. Six community state types (CSTs) were found where
groups 1, 3 and 5 were as previously discussed, composed primarily of L. crispatus, L. iners and L.
jensenii, respectively but group 4 (CST4) was explored more. CST4 was divided into two subgroups
on the basis of Gardnerella subgroups. Individuals with dominant Gardnerella subgroups A and C
separated into CST IVC and IVD, respectively, while those with dominant Gardnerella subgroup B
clustered within the heterogeneous CST IVA category [152]. In addition to gaining better insight into
Gardnerella, another study has used sequencing of the V4 region in the 16S rRNA genes to study the
role of Prevotella [153]. It was observed that Prevotella may act as the intermediate link between host
genetics and vaginal microbiome dynamics with Prevotella affecting the host metabolism or regulating
the functions of host genes. Furthermore, Prevotella is found in 72.2% of people’s vaginal microbiome
which is even higher than L. crispatus (36.9%) and L. iners (41.2%) [153].
Currently, the largest vaginal microbiome study analyzed 597 pregnancies and ~12000 samples [42].
The primary outcome was the identification of the signature vaginal microbes associated with preterm
birth (PTB): BVAB1, Prevotella cluster 2 (Prevotella timonensis and Prevotella buccalis), Sneathia amnii,
Megasphaera type1 and TM7-H1. PTB signatures were present more in the cohort of African American
women and identification of these species early pregnancy may help predict the likelihood of PTB [42].
This large scale data set also analyzed the vaginal microbiome during pregnancy of Caucasian and
African-American women [118]. Overall, alpha diversity in vaginal microbiome of non-pregnant
women was higher than the pregnant women. In African-American women, the vaginal microbiome
shifted towards a more Lactobacillus dominated profile from a highly diverse starting microbiome
over the course of pregnancy [118]. Metabolic simplification happens during the transition where
diversity decreases and most of the pathway reduction happens in first trimester in African pregnant
women [118].
5.3. Modeling Methodologies
Currently, very few modeling studies exist for the vaginal microbiome. Constraint-based methods
were used to reconstruct genome scale metabolic models (GEMs) for the several of the organisms
identified in the vaginal microbiome: TM7-H1, BVAB1 and L. crispatus [42,118]. They used functional
annotation information of these organisms with Enzyme Commission numbers to describe function
and KEGG IDs for nomenclature. Another study has employed a community metabolic modeling
approach where species-specific genes are considered based upon metagenomic data in the healthy
and diseased state [117]. These genes are then paired with metabolic reactions to find the community
metabolic potential (CMP) score for every metabolite in each sample [117]. CMP score variation shows
the variation in the metabolite abundances which helped them to identify the crucial metabolites.
Then, species, genes and reactions are identified which were responsible in giving that CMP score for a
metabolite. Bacterial vaginosis associated species (Eggerthella sp. 1, Megasphaera type 1, and Mageeibacillus
indolicus) have a substantial impact on the vaginal microbiome and were designated as “drivers” of
species-metabolite dynamics which caused metabolic variation in the vaginal microbiome [117].
6. Perspectives and Future Work
The human microbiome is an ecological setting where different microbial species are interacting
with each other through metabolite and protein exchange and is dynamic and complex in nature [3].
The diversity of microorganisms currently identified is high (Figure 2) and the relationships between
organisms can be either cooperative or competitive where microbes exchange the essential elements
for their own benefit or the dominant microbe may try to exploit the maximum resources using its own
metabolic network and secrete inhibitory agents against other microbes [154]. These interactions form
the basis of the working of the entire human microbiome. From these points, it is clear that human
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microbiome is not solely characterized or dependent on the working of a single microbe or single
species [34,155], but rather it must be studied as an interacting community. One approach that can
facilitate studying the human microbiome as an interacting, dynamic community is community genome
scale modeling [86]. However, challenges exist to utilizing genome scale modeling (GEM) including
the low number of models for human microbiome species and the need for further improvements in
computational frameworks for large-scale microbial communities (including appropriate objective
functions and compartmentalization issues) [28,35,154]. Ongoing research is working on identifying
and annotating novel human microbiome species which is needed as a basis for metabolic modeling.
Furthermore, once models are generated, details on material (protein, metabolite) exchange and
appropriate community objective functions need to be considered [6,21,36]. Advances in this manner
will aid in understanding the integrated function of the microbiome (interactions and temporal




Figure 2. Phylogenetic tree for the all the human microbes present at the 4 antomical sites (gut, oral,
skin, vagina). The disease caused by the resident human microbes is shown by a particular shape.
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The gut microbiome is the human microbiome with the largest number of species with greatest
diversity involved in many diseases including obesity and diabetes [72,73] [98]. Even though much
effort has gone into studying the gut microbiome, half of the total number of microbes in the gut
microbiome have not been annotated even at the genus level [68,78,82]. Additional knowledge of
species and molecular functions for obese and diabetic microbiomes will enable us to understand the
host and microbial metabolism aspects in a more detailed manner [49]. Disease, diet, geography, lifestyle
and even occupation are responsible for giving a unique gut microbiome for every individual as these
factors hugely alter the microbiome [48,60,66]. These alterations happening in this large-scale system
can be explored only by investigating the metabolic interactions among the microbes, microbe and
diet/host and for that, community-based genome scale metabolic modeling may help once annotated
species are identified [27,36]. Furthermore, the gut microbiome is involved in many biological functions
like carbohydrate metabolism, colonization resistance, and ROS production during cancer [39,53,64].
These biological processes individually are comprehensive in nature and both experimental and
computational investigations to the gut microbiome during each of these processes will give us many
novel findings and wide range of medical solutions.
Oral microbes live and form stable metabolic interactions in the biofilms [119,120]. Similar to
the gut microbiome, the oral microbiome is large (700+ different species) and has a large number of
unannotated species (between 50% [119] and 76% [123] unannotated). One reason for this low level of
species characterization in the oral microbiome is because oral microbes often form biofilms making
isolation and sequence analysis difficult. Thus, mechanisms of biofilm formation, maintenance and
dynamics need to be considered in studying the oral microbiome and oral diseases [125]. In addition,
novel biological mechanisms such as peptidic small molecules (PSMs) have been identified and are
responsible for giving structure to the oral microbiome [124]. Microbe–microbe interactions have
been explored less for this oral microbiome using modeling methods. Corynebacterium’s presence at
biofilm matrix for structuring the microbiome or P. gingivalis’s strategies during periodontitis occurs
only through stable metabolic interactions with their oral partners [119,121]. Performing GEM for just
P. gingivalis therefore will not give us the entire picture of the etiology of periodontitis as Benn et al.
suggested that it is never a single oral pathogen causing an oral disease [112,119]. Therefore, focus of
oral microbiome research should shift towards species identification and microbial interactions using
both experimental and computational methods. The oral microbiome, due to its topological position,
is heavily affected by food, smoke, alcohol, drugs and medication [114]. Genome scale models (GEM)
if performed to see these effects on oral microbiome will give us important therapeutic inferences. For
example, we can use GEM to investigate microbial metabolites and nicotine metabolites interactions
to assess the smoking effects. This type of study might give us the oral species utilizing the tobacco
metabolites which can be further used as drug targets to decrease the harmful smoking effects.
Skin microbes produce antimicrobial peptides against the foreign pathogens making the skin
microbiome highly involved in the immune mechanisms of the host [134,135]. Therefore, performing
detailed investigations on the skin microbiome can give us the idea on more kinds of immune strategies
taken by skin microbes. The dermatological disorders like acne, psoriasis, atopic dermatitis or primary
immunodeficient diseases (PIDs) are all caused by a particular bacterial trigger of host skin species [129].
These human health impacts occur due to the interesting property shown by skin microbes; switching
mechanism. Sebaceous skin harbors Propionobacterium acnes which switch from a host protective
commensal strain to a host damaging pathogenic strain causing acne [133]. Similarly, Staphylococcus
epidermis and Staphylococcus aureus also show these switching mechanisms to pathogenic strains
making them the causal agents for atopic dermatitis and PIDs [137]. Research has identified this
switching behavior of skin microbes but mechanisms associated genes, proteins, or pathways which
the microbes use to perform the switch have not been found yet. Serratia marcescens is another microbe
found in the skin microbiome during PIDs [136] and a genome scale model for this microbe has been
reconstructed [156] making it a candidate organism for studying microbial switching mechanisms.
The skin microbiome has been proved to be temporally highly stable and shows high interpersonal
Microorganisms 2020, 8, 197 20 of 28
variation [131,141]. Therefore, more time course studies to find out when exactly the skin microbiome
gets stable and unique in an individual should be performed. External factors significantly affect the
skin microbiome as it has been shown that the top 10 metabolites which affect the microbiome came
from cosmetics [116]. Skin microbiome’s research focus should move towards exploring the strange
mechanisms associated with this microbiome like high stability, high interpersonal variation, switching
mechanisms of the microbes and external effects. Albert Kligman and Donald Pillsbury, two renowned
dermatologists at the University of Pennsylvania in 1954 stated “a great deal more remains to be learned
about the forces which control the bacterial ecology of the surface of the skin” [138]. This remains as
true today as when this was originally stated in 1954.
The vaginal microbiome behaves differently than other microbiomes as consensus is starting
to identify core species found in the majority of healthy women, i.e., Lactobacillus [143]. However,
a diverse microbiome where Lactobacillus does not dominate has also been found in many healthy
women so it is still difficult to predict the effects of the microbiome based upon the dominant species.
For example, CST3 is a vagitype dominated by Lactobacillus iners, but CST3 is prone to bacterial
vaginosis because L. iners interacts with the main causative agent of this disease; BVAB1 [143,147].
Hence, having Lactobacillus dominated microbiome does not mean that person is not at risk, but a
high diversity vaginal microbiome almost always has a greater chance to transition to a diseased
microbiome [143–145]. Specific to the vaginal microbiome, evidence is arising demonstrating that
ethnicity may influence the vaginal microbiome composition. For example, the highly diverse vagitype
CST4 is found in 40% of black and Hispanic population making them more prone to bacterial vaginosis
and preterm birth [42,144,146]. The reason behind this disparity is currently not known. We have
a better understanding of what species are present in the vaginal microbiome during pregnancy,
preterm birth and bacterial vaginosis [42,118,148], but we need to know what functions individual
organisms are performing during these healthy and disease states, what type of metabolite exchanges
are happening between them, what kind of relationship, i.e., commensal or cooperative or competitive
is shown by them. The answers to these questions can be obtained by performing more GEM studies
on multiple vaginal microbes in their CSTs [42,118].
7. Conclusions
Human microbiome is a vast biological system where a great deal of knowledge is still unknown
including novel species and genes. The four main anatomical sites of the human microbiome (oral,
skin, gut and vaginal) harbor different sets of species and the species composition and the metabolic
interactions among them changes in response to many different variables, both intrinsic and extrinsic.
Furthermore, the species composition is also different for different individuals for all the microbiomes.
The complexity and variability of the human microbiome make it a potentially daunting area of
study, but the significance of the impacts of the human microbiome on human health warrant focused
research attention. While we are still at the phase of identifying and understanding the constituent
components of the human microbiome, it is necessary to push development of experimental and
computational methods that can help understand the large, interconnected, and dynamic system of the
human microbiome. Research studies in this direction will definitely help us to make bigger impact on
public health by creating effective medicinal strategies. It is expected that computational analyses will
be necessary to study the human microbiome to gain insight to the various metabolic mechanisms of
the microbe, its interaction partners, and if scaled up, the microbial niche at a particular anatomical
site and someday, the whole human microbiome.
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